NASDAQ · ABCL
Healthcare · Biotechnology
$13.78
Down-$0.63 (-4.57%)
Updated Oct 6, 2026, 11:51 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ABCL
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ABCL closed at $13.78 after 20 trading sessions, up 20.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $13.72 | $13.88 | $13.21 | $13.78 | 4.08M |
| Oct 2, 2026 | $14.095 | $14.303 | $13.66 | $13.74 | 3.71M |
| Oct 1, 2026 | $14.585 | $14.65 | $13.79 | $13.91 | 7.79M |
| Sep 30, 2026 | $14.78 | $15.015 | $14.56 | $14.59 | 4.86M |
| Sep 29, 2026 | $14.23 | $15.00 | $14.10 | $14.82 | 9.11M |
| Sep 28, 2026 | $12.44 | $14.2299 | $12.38 | $13.92 | 7.83M |
| Sep 25, 2026 | $12.74 | $12.93 | $12.29 | $12.70 | 3.38M |
| Sep 24, 2026 | $12.02 | $12.678 | $11.78 | $12.65 | 4.99M |
| Sep 23, 2026 | $12.54 | $12.6471 | $12.10 | $12.31 | 3.85M |
| Sep 22, 2026 | $12.56 | $12.97 | $12.49 | $12.65 | 4.29M |
| Sep 21, 2026 | $12.88 | $12.8999 | $12.43 | $12.66 | 4.43M |
| Sep 18, 2026 | $12.73 | $12.96 | $12.37 | $12.63 | 5.44M |
| Sep 17, 2026 | $12.15 | $13.18 | $11.99 | $12.73 | 8.05M |
| Sep 16, 2026 | $11.44 | $11.73 | $11.175 | $11.67 | 4.54M |
| Sep 15, 2026 | $11.17 | $11.69 | $10.90 | $11.41 | 3.73M |
| Sep 14, 2026 | $10.66 | $11.305 | $10.66 | $11.17 | 4.45M |
| Sep 11, 2026 | $10.55 | $10.955 | $10.32 | $10.89 | 4.38M |
| Sep 10, 2026 | $10.79 | $11.07 | $10.42 | $10.46 | 4.94M |
| Sep 9, 2026 | $11.37 | $11.45 | $11.01 | $11.05 | 2.41M |
| Sep 8, 2026 | $11.29 | $11.64 | $11.10 | $11.44 | 2.56M |
The latest Smart Investors Daily articles mentioning ABCL.
Company
Market Activity
Research & News
ABCL research
Company profile and research snapshot.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | JP Morgan | Overweight | — |
| Sep 24, 2026 | Goldman Sachs | Neutral | — |
| Aug 11, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Stifel | Buy | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Benzinga · Sep 29, 2026
JP Morgan analyst Brian Cheng initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $17.
Benzinga · Sep 24, 2026
Goldman Sachs analyst Andrea Newkirk reinstates AbCellera Biologics (NASDAQ:ABCL) with a Neutral and announces $13 price target.
Yahoo · Sep 16, 2026
VANCOUVER, British Columbia, September 16, 2026--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
SeekingAlpha · Sep 16, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABCL.
